Sophie Ugolini Inserm Research Director Innate Lymphoid Cells and Neural Regulation of Immunity team leader Unit 1104 – Center of Immunology Marseille-Luminy (CIML) firstname.lastname@example.org +33 (0)4 91 26 94 44
Cytomegalovirus (CMV) infection in a human being. In red and green, the natural killer (NK) cells try to make their way to the infected cell. Inserm/Jabrane-Ferrat, Nabila
In previous years, various studies have established a link between psychological stress and reduced immune defenses, but the mechanisms involved remained poorly elucidated. Sophie Ugolini, Inserm Research Director at the Center of Immunology Marseille-Luminy, and her colleagues at CNRS and Aix-Marseille Université have recently shown that such a link is to a large extent mediated by a type of receptor that binds to stress hormones: the β2-adrenergic receptor. Their findings have been published in Journal of Experimental Medicine.
For several years now, the scientific community has been interested in the effects of psychological stress on health. Studies have shown that when infection strikes, stress is linked to reduced immune defense system efficacy. With her team, Sophie Ugolini, Inserm Research Director at the Center of Immunology Marseille-Luminy (Inserm/CNRS/Aix-Marseille Université), has sought to explain the biological mechanisms behind this phenomenon. The researchers focused on receptors expressed on the surface of many of the body’s cells (including the immune cells) and which are specific to the stress hormones adrenaline and noradrenaline – the β2-adrenergic receptors.
To study their role, the team first reproduced a situation of chronic stress in mice by administering for seven days a molecule which, like the stress hormones, stimulates the β2-adrenergic receptors. They then exposed the animals to a virus from the herpes family, cytomegalovirus MCMV. The mortality rate of the “stressed” mice having received the molecule proved to be much higher than that of the untreated mice (90% versus 50%).
The researchers then evaluated the animals’ resistance to infection in the absence of these receptors. This involved taking mice that are genetically modified to be devoid of β2-adrenergic receptors and exposing them to cytomegalovirus. In these animals, the stress hormones could no longer bind to β2 receptors and as a consequence could no longer act. They presented much greater resistance to the viral infection (90% survival versus only 50% for the control mice). These initial findings therefore suggest that stimulation of the β2-adrenergic receptors by the stress hormones is responsible for the weakening of the immune system in situations of psychological stress.
Towards new therapeutic avenues
In order to better understand the mechanisms involved, the team also analyzed the immune response of the mice devoid of β2-adrenergic receptors. They observed an increased production of inflammatory cytokines – molecules produced by the immune cells which promote the elimination of viruses.
The researchers discovered that the β2-adrenergic receptors most particularly inhibit the response of certain immune cells, known as natural killer (NK) cells. Stimulated by the stress hormones, the β2-adrenergic receptors prevent the NK cells from producing a particular type of cytokine required in order to eliminate viruses.
“We have confirmed in an experimental setting that the stress hormones that bind to the β2-adrenergic receptors reduce immune response, which involves a decrease in the production of certain inflammatory cytokines required to eliminate viruses”, specifies Ugolini. According to the researcher, this study could open up new therapeutic avenues. “By targeting the β2-adrenergic receptor, it would in some disease settings be conceivable to deactivate the immune brakes triggered by states of stress”, she concludes.
A Marseille-based exploratory research taskforce, named EXPLORE COVID-19, analyzed immune cells in COVID-19 patients at different stages of the disease. The goal of the study was to gain translational insights to better understand the immune response in COVID-19 patients and identify potential ...
Back at the start of the pandemic, Inserm, through its REACTing consortium, set up Discovery: a European clinical trial to evaluate the efficacy of four antiviral drugs repurposed for the treatment of patients hospitalized with COVID-19 (remdesivir, hydroxychloroquine, lopinavir and interferon beta-1a). ...
β2-adrenergic signals downregulate the innate immune response and reduce host resistance to viral infection Elisabeth Wieduwild1, Mathilde Girard-Madoux1, Linda Quatrini1,2, Caroline Laprie1, Lionel Chasson1, Rafaëlle Rossignol1, Claire Bernat1, Sophie Guia1, and Sophie Ugolini1 1 Aix Marseille Univ, CNRS, INSERM, CIML, Centre d’Immunologie de Marseille-Luminy, Marseille, France 2 Department of Immunology, IRCSS Bambino Gesù Children’s Hospital, Rome, Italy Journal of Experimental Medicine : https://doi.org/10.1084/jem.20190554